Ascletis says ASC37 triple agonist posts 88% greater weight loss than tirzepatide in obese mice

PUBT · 1d ago
Ascletis says ASC37 triple agonist posts 88% greater weight loss than tirzepatide in obese mice
  • Ascletis reported preclinical results for ASC37, a GLP-1R/GIPR/GCGR triple agonist designed for once-monthly subcutaneous dosing.
  • In diet-induced obese mice, ASC37 cut body weight 14.1% versus 7.5% for tirzepatide at 1 nmol/kg over 11 days.
  • ASC37 delivered up to 41.5% weight loss at higher doses in the same model.
  • IND submissions for ASC37 once-monthly subcutaneous formulation and an oral formulation targeted for Q3 2026.
  • Non-human primate data showed an average observed half-life of about 17 days for ASC37 versus 2.5 days for retatrutide.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260727-12257534), on July 27, 2026, and is solely responsible for the information contained therein.